$RDGL
VIVOS INC Stock $rdgl

$rdgl Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223006366 Filed on March 01, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$6.000K	$6.500K	$36.50K
YoY Change	-53.85%		145.12%
Cost Of Revenue	$7.536K	$10.73K	$28.78K
YoY Change	151.2%	-10.58%	139.83%
Gross Profit	-$1.536K	-$4.230K	$7.720K
YoY Change	-115.36%	-64.75%	167.13%
Gross Profit Margin	-25.6%	-65.08%	21.15%
Selling, General & Admin	$200.4K	$669.7K	$2.182M
YoY Change	-70.74%	356.35%	-1.63%
% of Gross Profit			28259.97%
Research & Development	$46.38K	$31.74K	$343.8K
YoY Change	-36.1%	-46.83%	19.85%
% of Gross Profit			4453.39%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$246.8K	$701.4K	$2.525M
YoY Change	-67.42%	239.77%	0.83%
Operating Profit	-$248.3K	-$705.6K	-$2.518M
YoY Change	-66.78%	223.04%	0.64%
Interest Expense		$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net			$47.59K
YoY Change
Pretax Income	-$248.3K	-$705.7K	-$2.470M
YoY Change	-64.52%	295.92%	-2.28%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$248.3K	-$705.7K	-$2.470M
YoY Change	-64.52%	295.92%	-2.28%
Net Earnings / Revenue	-4138.63%	-10856.15%	-6767.75%
Basic Earnings Per Share	$0.00		-$0.01
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	362.5M shares	359.9M shares	351.4M shares
Diluted Shares Outstanding	362.5M shares		351.4M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.412M	$1.706M	$1.706M
YoY Change	15.6%	6.22%	6.22%
Cash & Equivalents	$1.412M	$1.706M
Short-Term Investments
Other Short-Term Assets	$49.28K	$25.67K	$25.67K
YoY Change	-32.54%	-8.91%	-8.91%
Inventory
Prepaid Expenses	$49.28K	$25.67K
Receivables		$11.00K	$11.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.462M	$1.743M	$1.743M
YoY Change	11.76%	6.64%	6.64%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$1.462M	$1.743M	$1.743M
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$1.462M	$1.743M	$1.743M
YoY Change	11.76%	6.64%	6.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$48.99K	$81.69K	$81.69K
YoY Change	-42.72%	-51.06%	-51.06%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$48.99K	$81.69K	$81.69K
YoY Change	-42.72%	-51.06%	-51.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.99K	$81.69K	$81.69K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$48.99K	$81.69K	$81.69K
YoY Change	-42.72%	-51.06%	-51.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$79.80M	-$79.56M
YoY Change		3.2%
Common Stock	$71.58M	$71.58M
YoY Change		3.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.413M	$1.661M	$1.661M
YoY Change
Total Liabilities & Shareholders Equity	$1.462M	$1.743M	$1.743M
YoY Change	11.76%	6.64%	6.64%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$248.3K	-$705.7K	-$2.470M
YoY Change	-64.52%	295.92%	-2.28%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$293.6K	-$281.7K	-$1.120M
YoY Change	-23.59%	19.62%	16.21%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	$1.220M
YoY Change		-100.0%	-26.78%
NET CHANGE
Cash From Operating Activities	-$293.6K	-281.7K	-$1.120M
Cash From Investing Activities
Cash From Financing Activities		0.000	$1.220M
Net Change In Cash	-$293.6K	-281.7K	$99.94K
YoY Change		-25.97%	-85.77%
FREE CASH FLOW
Cash From Operating Activities	-$293.6K	-$281.7K	-$1.120M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	36693047	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	362541528	shares
CY2022	dei	Auditor Firm AuditorFirmId	5525
CY2022	dei	Auditor Name AuditorName	Fruci & Associates II, PLLC
CY2022	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1706065	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1606123	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	25671	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	28175	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1742736	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1634298	usd
CY2022Q4	us-gaap	Assets Assets	1742736	usd
CY2021Q4	us-gaap	Assets Assets	1634298	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	81692	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	166915	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	81692	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	166915	usd
CY2022Q4	us-gaap	Liabilities Liabilities	81692	usd
CY2021Q4	us-gaap	Liabilities Liabilities	166915	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	362541528	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	362541528	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	343530678	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	343530678	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	362541	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	343531	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	71217954	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	68573142	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79556028	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77085867	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1661044	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1467383	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1742736	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1634298	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36499	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14887	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28779	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001449349
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2022	RDGL	Forgiveness Of Debt ForgivenessOfDebt		usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022	RDGL	Stock Issued During Period Value Fractional Adjustment StockIssuedDuringPeriodValueFractionalAdjustment		usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2021	RDGL	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises		usd
CY2022	RDGL	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises		usd
CY2022	RDGL	Forgiveness Of Debt ForgivenessOfDebt		usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities		usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet		usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2022	RDGL	Repayments Of Related Party Notes RepaymentsOfRelatedPartyNotes		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2022	RDGL	Conversion Of Notes Payable And Accrued Interest For Common And Common Stock ConversionOfNotesPayableAndAccruedInterestForCommonAndCommonStock		usd
CY2022	RDGL	Conversion Of Notes Payable Related Parties And Accrued Interest Into Common Stock ConversionOfNotesPayableRelatedPartiesAndAccruedInterestIntoCommonStock		usd
CY2022	RDGL	Rsus Vested Into Common Stock RsusVestedIntoCommonStock		usd
CY2022	RDGL	Stock Options Exercised For Recission Of Common And Preferred Stock StockOptionsExercisedForRecissionOfCommonAndPreferredStock		usd
CY2022	RDGL	Common Stock Issued In Settlement Of Accounts Payable Related Parties CommonStockIssuedInSettlementOfAccountsPayableRelatedParties		usd
CY2022	RDGL	Restricted Stock Units Vested Into Common Stock RestrictedStockUnitsVestedIntoCommonStock		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021	RDGL	Weighted Average Exercise Price Per Share Options Granted WeightedAverageExercisePricePerShareOptionsGranted
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021	RDGL	Weighted Average Exercise Price Per Share Options Exercised WeightedAverageExercisePricePerShareOptionsExercised
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021	RDGL	Weighted Average Exercise Price Per Share Options Expired WeightedAverageExercisePricePerShareOptionsExpired
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	RDGL	Weighted Average Exercise Price Per Share Options Granted WeightedAverageExercisePricePerShareOptionsGranted
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	RDGL	Weighted Average Exercise Price Per Share Options Exercised WeightedAverageExercisePricePerShareOptionsExercised
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022	RDGL	Weighted Average Exercise Price Per Share Options Expired WeightedAverageExercisePricePerShareOptionsExpired
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	RDGL	Income Tax Reconciliation Nondeductible Expense Forgiveness Of Debt IncomeTaxReconciliationNondeductibleExpenseForgivenessOfDebt		usd
CY2022	RDGL	Income Tax Reconciliation Related Party Accrual IncomeTaxReconciliationRelatedPartyAccrual		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	0-53497
CY2022	dei	Entity Registrant Name EntityRegistrantName	VIVOS INC
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	80-0138937
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	719 Jadwin Avenue
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Richland
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	99352
CY2022	dei	City Area Code CityAreaCode	(509)
CY2022	dei	Local Phone Number LocalPhoneNumber	736-4000
CY2022	dei	Security12g Title Security12gTitle	Common Stock, $0.001 Par Value
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12000	usd
CY2022	us-gaap	Gross Profit GrossProfit	7720	usd
CY2021	us-gaap	Gross Profit GrossProfit	2887	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	1755316	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	1838323	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	275240	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	267477	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	343802	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286848	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	151111	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	112037	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2525469	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2504685	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2517749	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2501798	usd
CY2021	us-gaap	Interest Expense InterestExpense	25375	usd
CY2021	RDGL	Forgiveness Of Debt ForgivenessOfDebt	136445	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	47588	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-137038	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	47588	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-25968	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2470161	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2527766	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2470161	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2527766	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	351425912	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	325851906	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	32034	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1800000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	412011	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	122110	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3756	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11238	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1614000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2527766	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1467383	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1467383	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1467383	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1200000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	49242	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4880	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	20000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1389700	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2470161	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1661044	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1661044	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4880	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2470161	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2527766	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3756	usd
CY2022	RDGL	Restricted Stock Units Issued For Services RestrictedStockUnitsIssuedForServices	1389700	usd
CY2021	RDGL	Restricted Stock Units Issued For Services RestrictedStockUnitsIssuedForServices	1614000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	47588	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-137038	usd
CY2021	RDGL	Forgiveness Of Debt ForgivenessOfDebt	136445	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2504	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5660	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	11607	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	31480	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-66143	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-25399	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1350103	usd
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1563947	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1120058	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-963819	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	45000	usd
CY2021	RDGL	Repayments Of Related Party Notes RepaymentsOfRelatedPartyNotes	-100000	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1220000	usd
CY2021	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1811238	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1220000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1666238	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	99942	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	702419	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1606123	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	903704	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1706065	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1606123	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	50773	usd
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	94515	usd
CY2021	RDGL	Conversion Of Notes Payable And Accrued Interest For Common And Common Stock ConversionOfNotesPayableAndAccruedInterestForCommonAndCommonStock	185346	usd
CY2021	RDGL	Conversion Of Notes Payable Related Parties And Accrued Interest Into Common Stock ConversionOfNotesPayableRelatedPartiesAndAccruedInterestIntoCommonStock	50370	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	2950	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	6714	usd
CY2021	RDGL	Rsus Vested Into Common Stock RsusVestedIntoCommonStock	12000	usd
CY2022	RDGL	Accounts Payable Converted Into Shares Of Common Stock AccountsPayableConvertedIntoSharesOfCommonStock	49242	usd
CY2021	RDGL	Accounts Payable Converted Into Shares Of Common Stock AccountsPayableConvertedIntoSharesOfCommonStock	90000	usd
CY2021	RDGL	Stock Options Exercised For Recission Of Common And Preferred Stock StockOptionsExercisedForRecissionOfCommonAndPreferredStock	60000	usd
CY2021	RDGL	Common Stock Issued In Settlement Of Accounts Payable Related Parties CommonStockIssuedInSettlementOfAccountsPayableRelatedParties	32110	usd
CY2021	RDGL	Restricted Stock Units Vested Into Common Stock RestrictedStockUnitsVestedIntoCommonStock	12000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Description Of Credit Risk Exposure DescriptionOfCreditRiskExposure	half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	2500000	usd
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	50000000	shares
CY2021Q3	us-gaap	Share Price SharePrice	0.10
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5000000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1200000	usd
CY2022Q3	us-gaap	Share Price SharePrice	0.08
CY2022Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	15000000	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	20000000	shares
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	20000	usd
CY2022Q4	RDGL	Stock Issued During Period Value Remaining New Issues StockIssuedDuringPeriodValueRemainingNewIssues	3800000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	2500000	usd
CY2022	RDGL	Offering Term OfferingTerm	Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States.
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1706065	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zWtP8V82zF18" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zNeutFnCZiYk">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpro8JFVubrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrgGcZGwClF1">Financial Statement Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Production Costs ProductionCosts	2500	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1500	usd
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	64762379	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	69287379	shares
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	343802	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286848	usd
CY2022	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Estimated Range Not Possible SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible	The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next twelve months
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	237000	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	0	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	0	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	950000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	362541528	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	362541528	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	343530678	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	343530678	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	RDGL	Functional Adjustment Shares FunctionalAdjustmentShares	90	shares
CY2022Q3	us-gaap	Share Price SharePrice	0.08
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	20000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-176295	usd
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1800000	usd
CY2021Q1	RDGL	Warrant Purchase WarrantPurchase	11238	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	77768	shares
CY2021Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3756	usd
CY2021Q4	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	185346	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	28885461	shares
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M25D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1661429	usd
CY2020Q4	RDGL	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice	0.05
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2500000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	24132652	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2252809	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	83992	usd
CY2021Q4	RDGL	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice	0.04
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2252809	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16032	usd
CY2022Q4	RDGL	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice	0.04
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2252809	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	16032	usd
CY2022Q4	RDGL	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Per Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares	0.04
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.66	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.03	pure
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	1389700	usd
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense	1614000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	30955700	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022	RDGL	Restricted Stock Expenses Yet To Be Recognized RestrictedStockExpensesYetToBeRecognized	1055400	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6500000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6280000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	3400	usd
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	3400	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6503400	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6283400	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-518700	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-530800	usd
CY2021	RDGL	Income Tax Reconciliation Nondeductible Expense Forgiveness Of Debt IncomeTaxReconciliationNondeductibleExpenseForgivenessOfDebt	-28700	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation IncomeTaxReconciliationNondeductibleExpenseDepreciation	-1100	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Depreciation IncomeTaxReconciliationNondeductibleExpenseDepreciation	-1100	usd
CY2021	RDGL	Income Tax Reconciliation Related Party Accrual IncomeTaxReconciliationRelatedPartyAccrual	-6400	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	291800	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	339700	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	10500	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	25700	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	217500	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	201600	usd

Files In Submission

Name	View Source	Status
0001493152-23-006366-index-headers.html	Edgar Link	pending
0001493152-23-006366-index.html	Edgar Link	pending
0001493152-23-006366.txt	Edgar Link	pending
0001493152-23-006366-xbrl.zip	Edgar Link	pending
ex23.htm	Edgar Link	pending
ex23_002.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
rdgl-20221231.xsd	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
rdgl-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
rdgl-20221231_def.xml	Edgar Link	unprocessable
rdgl-20221231_lab.xml	Edgar Link	unprocessable
rdgl-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RDGL
VIVOS INC Stock $rdgl

2023 Q1 Form 10-K Financial Statement

#000149315223006366 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RDGL VIVOS INC Stock $rdgl

2023 Q1 Form 10-K Financial Statement

#000149315223006366 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RDGL
VIVOS INC Stock $rdgl